Suchergebnisse - "Shah, Rashmi R"

PubPharm (12)

1

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

enthalten in: Medical toxicology | 2017

von Shah, R.

2

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

enthalten in: Drug safety | 2017

von Shah, R.

3

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Medical toxicology | 2015

von Shah, R. | Morganroth, J.

4

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

enthalten in: Drug safety | 2015

von Shah, R. | Morganroth, J.

5

Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients

enthalten in: Medical toxicology | 2014

von Shah, D. | Dholakia, S. | Shah, R.

6

Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients

enthalten in: Drug safety | 2014

von Shah, D. | Dholakia, S. | Shah, R.

7

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

enthalten in: Medical toxicology | 2013

von Shah, R. | Morganroth, J. | Shah, D.

8

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

enthalten in: Medical toxicology | 2013

von Shah, D. | Shah, R. | Morganroth, J.

9

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

enthalten in: Medical toxicology | 2013

von Shah, R. | Morganroth, J. | Shah, D.

10

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.